Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1080/17441692.2021.1924223 http://scihub22266oqcxt.onion/10.1080/17441692.2021.1924223 33966604!8453042!33966604     free     free     free Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Glob+Public+Health 2021 ; 16 (10): 1523-1536 Nephropedia Template TP {{tp|p=33966604|t=2021. Breaking Bad Patents: Learning from HIV/AIDS to make COVID-19 treatments accessible |pdf=|usr=}}{{33966604}} gab.com Text Breaking Bad Patents: Learning from HIV/AIDS to make COVID-19 treatments accessible JO: Glob Public Health http://www.kidney.de/pget.php?&tw=1&pmid=33966604 #FOAvip The COVID-19 pandemic has brought renewed attention to the topic of challenging drug patents in the interest of public health. Pharmaceutical companies have already begun to patent existing medicines for the treatment and prevention of SARS-CoV-2, affording them exclusive manufacturing rights over vital medicines. Advocates have raised concerns regarding the pricing of COVID-19 drugs, as well as patent monopolies on the manufacture of COVID-19 treatments. The HIV/AIDS pandemic provides a useful lens through which we can analyse existing pathways for challenging pharmaceutical patents in the context of global pandemic. In this article, we review three legal pathways for overriding and seizing patents on medicines by describing cases in which they were employed to make antiretroviral drugs more accessible to people living with HIV. Last, we highlight the weaknesses inherent in these pathways and offer advocacy and policy suggestions for how to strengthen these pathways to improve access to COVID-19 treatments as they become available in the United States and globally. Twit Text FOAVip Breaking Bad Patents: Learning from HIV/AIDS to make COVID-19 treatments accessible ????Glob Public Health http://www.kidney.de/pget.php?&tw=1&pmid=33966604 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=33966604 #FOAvip English Wikipedia <ref>{{Cite pmid|33966604}}</ref> Breaking Bad Patents: Learning from HIV/AIDS to make COVID-19 treatments accessible #MMPMID33966604 D'Angelo AB; Grov C; Johnson J; Freudenberg N Glob Public Health 2021[Oct]; 16 (10): 1523-1536 PMID33966604show ga The COVID-19 pandemic has brought renewed attention to the topic of challenging drug patents in the interest of public health. Pharmaceutical companies have already begun to patent existing medicines for the treatment and prevention of SARS-CoV-2, affording them exclusive manufacturing rights over vital medicines. Advocates have raised concerns regarding the pricing of COVID-19 drugs, as well as patent monopolies on the manufacture of COVID-19 treatments. The HIV/AIDS pandemic provides a useful lens through which we can analyse existing pathways for challenging pharmaceutical patents in the context of global pandemic. In this article, we review three legal pathways for overriding and seizing patents on medicines by describing cases in which they were employed to make antiretroviral drugs more accessible to people living with HIV. Last, we highlight the weaknesses inherent in these pathways and offer advocacy and policy suggestions for how to strengthen these pathways to improve access to COVID-19 treatments as they become available in the United States and globally. |*Acquired Immunodeficiency Syndrome[MESH] |*COVID-19 Drug Treatment[MESH] |Drug Industry[MESH] |Humans[MESH] |Pandemics/prevention & control[MESH] |SARS-CoV-2[MESH]Breaking Bad Patents: Learning from HIV/AIDS to make COVID-19 treatmen(epmc).pdf DeepDyve Pubget Overpricing